Cargando…
BAY 58-2667, an NO-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts
Autores principales: | Krieg, Thomas, Liu, Yanping, Rütz, Thomas, Methner, Carmen, Yang, Xi-Ming, Felix, Stephan B, Downey, James M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313348/ http://dx.doi.org/10.1186/1471-2210-9-S1-P36 |
Ejemplares similares
-
The Soluble Guanylyl Cyclase Activator Bay 58-2667 Selectively Limits Cardiomyocyte Hypertrophy
por: Irvine, Jennifer C., et al.
Publicado: (2012) -
Antihypertrophic actions of NO-independent soluble guanylyl cyclase (sGC) ligands BAY 41-2272 and BAY 58-2667 in vitro
por: Ritchie, Rebecca, et al.
Publicado: (2009) -
Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
por: Frey, Reiner, et al.
Publicado: (2011) -
Pharmacological preconditioning with the guanylate cyclase activator cinaciguat (BAY 58-2667) protects against reperfusion injury after cardiopulmonary bypass
por: Radovits, Tamás, et al.
Publicado: (2009) -
Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
por: Scheerans, Christian, et al.
Publicado: (2011)